Natco Pharma CEO Donates Rs 15 Crore to L V Prasad Eye Institute for children eye care

Published On 2017-06-24 05:57 GMT   |   Update On 2017-06-24 05:57 GMT

Hyderabad: Mr Rajeev Nannapaneni, Vice Chairman and CEO, Natco Pharma Limited, donated 1.5 lakh shares valued at Rs 15 crores to Hyderabad Eye Research Foundation, the research arm of L V Prasad Eye Institute, to find innovative approaches to tackle the problems of blindness and visual impairment in children that can benefit India and other developing countries.


Accepting this donation, Dr Gullapalli N Rao, Founder and Chair, L V Prasad Eye Institute (LVPEI) said, “It is exciting to see such spirit of generosity in youngsters like Rajeev and his wife, Swathi. This support will allow us to transform our efforts in children’s eye health and create a global resource centre with huge impact throughout the developing world. Millions of children will be treated by this act of generosity.”


In 2016-17, children constituted 18% of LVPEI’s patient profile across locations.


The Child Sight Institute is a children’s eye health division of LVPEI, encompassing all children’s eye health programmes that LVPEI are engaged in.


This includes care at all levels from primary to advanced tertiary across four states – Telangana, Andhra Pradesh, Odisha and Karnataka. Every form of children’s eye problems can be treated at this Institute irrespective of the person’s ability to pay.


In addition, this Institute will have partnerships with multiple centres in India and the developing countries. In education and research, it will build on existing collaborations with leading institutes in the US, Europe and Asia.

Article Source : PRESS RELEASE

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News